Joe E. Kiani Sells 4,300 Shares of Masimo Corp. (MASI) Stock
Masimo Corp. (NASDAQ:MASI) CEO Joe E. Kiani sold 4,300 shares of the firm’s stock in a transaction dated Tuesday, October 4th. The shares were sold at an average price of $60.07, for a total value of $258,301.00. Following the transaction, the chief executive officer now directly owns 121,441 shares of the company’s stock, valued at approximately $7,294,960.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Masimo Corp. (NASDAQ:MASI) opened at 59.85 on Friday. The firm has a market cap of $2.95 billion, a price-to-earnings ratio of 31.38 and a beta of 0.70. Masimo Corp. has a 52-week low of $33.03 and a 52-week high of $60.52. The company has a 50 day moving average price of $59.06 and a 200-day moving average price of $51.33.
Masimo Corp. (NASDAQ:MASI) last issued its quarterly earnings data on Wednesday, August 3rd. The company reported $0.57 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.16. Masimo Corp. had a return on equity of 29.07% and a net margin of 15.40%. The firm earned $172.64 million during the quarter, compared to the consensus estimate of $166.02 million. During the same quarter in the previous year, the company posted $0.36 EPS. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. Equities research analysts anticipate that Masimo Corp. will post $2.02 EPS for the current year.
A number of institutional investors have recently modified their holdings of MASI. Mitra Capital LLC acquired a new position in shares of Masimo Corp. during the first quarter valued at about $4,387,000. Adams Diversified Equity Fund Inc. acquired a new position in shares of Masimo Corp. during the second quarter valued at about $530,000. First Republic Investment Management Inc. acquired a new position in shares of Masimo Corp. during the first quarter valued at about $12,638,000. Nationwide Fund Advisors increased its position in shares of Masimo Corp. by 1.9% in the second quarter. Nationwide Fund Advisors now owns 235,881 shares of the company’s stock valued at $12,387,000 after buying an additional 4,403 shares during the last quarter. Finally, Eaton Vance Management acquired a new position in shares of Masimo Corp. during the second quarter valued at about $1,126,000. Hedge funds and other institutional investors own 79.88% of the company’s stock.
Several brokerages recently weighed in on MASI. Zacks Investment Research cut Masimo Corp. from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. BTIG Research reaffirmed a “hold” rating on shares of Masimo Corp. in a research note on Friday, August 5th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $55.00 target price (up previously from $52.00) on shares of Masimo Corp. in a research note on Friday, August 5th. Finally, Wedbush reaffirmed an “outperform” rating and set a $63.00 target price (up previously from $60.00) on shares of Masimo Corp. in a research note on Thursday, August 4th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Masimo Corp. currently has an average rating of “Buy” and a consensus target price of $52.60.
Masimo Corp. Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets non-invasive patient monitoring products. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring.
Receive News & Stock Ratings for Masimo Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Corp. and related stocks with our FREE daily email newsletter.